Prioritization of initiatives 2024-2027 of the strategic map of pharmaceutical outpatient care of the Spanish Society of Hospital Pharmacy. / Priorización de iniciativas 2024­2027 del mapa estratégico de atención farmacéutica al paciente externo de la Sociedad Española de Farmacia Hospitalaria.

OBJECTIVE: To prioritize the initiatives to be developed for the development of the Strategic Map of Outpatient Care (MAPEX) project to improve the quality of care and Pharmaceutical Care for patients seen in Hospital Pharmacy outpatient clinics in the period 2024-2027 in Spain. METHOD: The study was carried out in 4 phases between January and December 2023. For phase 1, a literature review of the evolution of the project was carried out by the coordinating committee with the aim of establishing a basis on which to define a new proposal for initiatives. In addition, an analysis was made of the health trends that will have an impact in the coming years. In phase 2, a working group of 19 specialists from all the autonomous communities was created, who were called regional ambassadors. They all made a preliminary proposal of initiatives and established revisions for their adjustment and final version both online and in telematic meetings. In phase 3, a consensus was established based on the Delphi-Rand/UCLA methodology with two rounds of online voting to select the initiatives classified as: priority and key or breakthrough. Between the first and second round of voting, a face-to-face "Consensus Conference" was held, where the results of the first round were presented. In phase 4, a public presentation was made in scientific forums and through the web. RESULTS: Ten trends in the health sector were identified. A list of 34 initiatives grouped into five lines of work was established. A total of 103 panelists participated in the first round and 76 in the second. Finally, five initiatives were established as priority and 29 as key. Among those prioritized were external visibility, adaptations to the CMO methodology, strengthening certification and improving training. CONCLUSIONS: The initiatives agreed upon as priorities were aimed at improving professional visibility, broadening the methodology of care work, expanding the quality of care, enhancing the training of professionals and the voice of patients.

TELEA-Farmacia: Pharmaceutical care by Telepharmacy to oncology patients from a hospital pharmacy service.

OBJECTIVE: To describe the implementation of a pilot Telepharmacy project (TELEA-Farmacia) in adult patients with cancer, analyze the results obtained, and identify opportunities for improvement, from a hospital  pharmacy service. METHOD: Between October and December 2021, oncology patients, collecting  their oral antineoplastic drugs at the Unit of Oncology Pharmacy of the hospital pharmacy service were stratified using the MAPEX model. Oncology patients  candidates for inclusion in the TELEA-Farmacia project included "medium-high  priority" hospital pharmacy patients, along with oncology patients who,  according to pharmacist's opinion, could benefit from Telepharmacy. On a  weekly basis, oncology patients recorded on the TELEA platform their biological  measurements and completed the questionnaires on medication  adherence and pain. Questionnaires on quality of life were completed on a  monthly basis. To score health indicators, oncology patients accessed TELEA  through the SERGAS-MOBIL app or a web browser. Follow-up of health  indicators was performed by the Unit of Oncology Pharmacy of the hospital  pharmacy service. RESULTS: The study sample included 29 oncology patients (48% were male)  with a mean age of 59 years (44-75). According to the stratification model,  31% were low-priority patients, 62% had medium-priority, and 7%  had high  priority. The digital gap in patients with advanced ages was the main obstacle  to inclusion. Reports were monitored daily, and a total of 364 responses were  received. In the presence of alarming reports and/or out-of-range values,  active monitoring and/or telephonic follow-up were initiated. Pharmaceutical  care was adapted to the health problem detected according to individual  patient needs. CONCLUSIONS: The Telemedicine pilot project TELEA-Farmacia made it possible  to test TELEA in patients with cancer in a real-life context. TELEA facilitated  continuous follow-up, early detection of drug-related problems, and the  identification of new needs and improvement points. To such purpose, clinical  oncology pharmacists combined face-to-face consults with patient stratification  and remote follow-up. This study demonstrated that new  stratification models are necessary in hospital pharmacy services to identify  patients with technology skills who can benefit from using Telemedicine tools  as TELEA.

OBJETIVO: Describir la implantación de un proyecto piloto de Telefarmacia (TELEA-Farmacia) en el paciente oncológico adulto y analizar los resultados recabados, así como identificar las oportunidades de mejora, desde un servicio de farmacia hospitalario.Método: Entre octubre y diciembre de 2021, los pacientes oncológicos a  tratamiento con antineoplásicos orales citados en la consulta de farmacia oncológica del servicio de farmacia de hospital fueron estratificados a  través del modelo MAPEX. Se consideraron susceptibles de inclusión en TELEA- Farmacia a quienes requerían atención farmacéutica con "prioridad media-alta" y a aquellos que, según criterio farmacéutico, pudieran beneficiarse de la herramienta. A través del aplicativo TELEA se programaron semanalmente biomedidas y cuestionarios de adherencia y evaluación del  dolor, y mensualmente un cuestionario de calidad de vida. Accediendo a TELEA  mediante la aplicación móvil SERGAS-MÓBIL o un navegador web, los  pacientes oncológicos respondieron a los indicadores de salud programados, de cuyo seguimiento fue responsable la Unidad de Farmacia Oncológica del  servicio de farmacia de hospital. RESULTADOS: Se incluyeron 29 pacientes oncológicos (48% hombres), con una  media de 59 años (44-75). Un 31% fueron de prioridad baja, 62% media y 7%  alta según el modelo de estratificación, siendo la brecha digital existente  en edades avanzadas el principal impedimento para la inclusión. Se realizó un  seguimiento diario de las notificaciones, recibiéndose un total de 364  respuestas. A partir de las consideradas alarmantes y de los valores fuera de  rango, se procedió al seguimiento activo y/o contacto telefónico,  proporcionando atención farmacéutica adaptada al problema de salud  detectado en función de las necesidades. CONCLUSIONES: El proyecto piloto de Telemedicina TELEA-Farmacia permitió testar la herramienta en pacientes oncológicos en vida real, facilitando el seguimiento continuado, la detección temprana de problemas  relacionados con medicamentos y la identificación de nuevas necesidades y  puntos de mejora para su implantación definitiva en la actividad asistencial.  Para ello, fue necesario compaginar la actividad presencial en consulta con el tiempo requerido para la estratificación y seguimiento telemático. Además, ha evidenciado la necesidad de disponer de nuevos modelos de  estratificación en un servicio de farmacia de hospital para la atención  farmacéutica que contemplen el manejo de las tecnologías por parte de los  pacientes, para identificar así a quienes más se puedan beneficiar de la  herramienta de Telemedicina TELEA.

TELEA-Farmacia: Atención farmacéutica mediante Telefarmacia a pacientes oncológicos desde un servicio de farmacia hospitalaria / TELEA-Farmacia: Pharmaceutical care by Telepharmacy to oncology patients from a hospital pharmacy service

Objetivo: Describir la implantación de un proyecto piloto de Telefarmacia (TELEA-Farmacia) en el paciente oncológico adulto y analizar losresultados recabados, así como identificar las oportunidades de mejora,desde un servicio de farmacia hospitalario.Método: Entre octubre y diciembre de 2021, los pacientes oncológicosa tratamiento con antineoplásicos orales citados en la consulta de farmaciaoncológica del servicio de farmacia de hospital fueron estratificados a travésdel modelo MAPEX. Se consideraron susceptibles de inclusión en TELEA-Farmacia a quienes requerían atención farmacéutica con “prioridad media-alta”y a aquellos que, según criterio farmacéutico, pudieran beneficiarse de laherramienta. A través del aplicativo TELEA se programaron semanalmentebiomedidas y cuestionarios de adherencia y evaluación del dolor, y mensualmente un cuestionario de calidad de vida. Accediendo a TELEA mediantela aplicación móvil SERGAS-MÓBIL o un navegador web, los pacientesoncológicos respondieron a los indicadores de salud programados, de cuyoseguimiento fue responsable la Unidad de Farmacia Oncológica del serviciode farmacia de hospital.Resultados: Se incluyeron 29 pacientes oncológicos (48% hombres),con una media de 59 años (44-75). Un 31% fueron de prioridad baja,62% media y 7% alta según el modelo de estratificación, siendo la brecha. digital existente en edades avanzadas el principal impedimento para lainclusión. Se realizó un seguimiento diario de las notificaciones, recibiéndose un total de 364 respuestas. A partir de las consideradas alarmantesy de los valores fuera de rango, se procedió al seguimiento activo y/ocontacto telefónico, proporcionando atención farmacéutica adaptada alproblema de salud detectado en función de las necesidades. (AU)

Objective: To describe the implementation of a pilot Telepharmacy project (TELEA-Farmacia) in adult patients with cancer, analyze the resultsobtained, and identify opportunities for improvement, from a hospital pharmacy service.Method: Between October and December 2021, oncology patients,collecting their oral antineoplastic drugs at the Unit of Oncology Pharmacy of the hospital pharmacy service were stratified using the MAPEXmodel. Oncology patients candidates for inclusion in the TELEA-Farmaciaproject included “medium-high priority” hospital pharmacy patients, alongwith oncology patients who, according to pharmacist’s opinion, couldbenefit from Telepharmacy. On a weekly basis, oncology patients recorded on the TELEA platform their biological measurements and completedthe questionnaires on medication adherence and pain. Questionnaires onquality of life were completed on a monthly basis. To score health indicators, oncology patients accessed TELEA through the SERGAS-MOBIL appor a web browser. Follow-up of health indicators was performed by theUnit of Oncology Pharmacy of the hospital pharmacy service.Results: The study sample included 29 oncology patients (48% weremale) with a mean age of 59 years (44-75). According to the stratificationmodel, 31% were low-priority patients, 62% had medium-priority, and 7%. had high priority. The digital gap in patients with advanced ages was themain obstacle to inclusion. Reports were monitored daily, and a total of364 responses were received. In the presence of alarming reports and/orout-of-range values, active monitoring and/or telephonic follow-up wereinitiated. Pharmaceutical care was adapted to the health problem detected according to individual patient needs. (AU)